Background and Objective
- •Thousand three hundred and eight eligible trials related to COVID-19 were registered up to May 15th, 2020.
- •Trials were planned in 71 countries, with most in Europe.
- •Although more than half of the trials were already recruiting, eight had peer-reviewed publications.
- •The research community has shown a good response to the pandemic in terms of initiating trials.
What this adds to what was known?
- •The ultimate test will be whether the research community will be able to generate the needed evidence to guide the management of the pandemic.
- •Efforts should focus on completing the trials and publishing them in a timely fashion.
What is the implication and what should change now?
Naming the coronavirus disease (COVID-19) and the virus that causes it.
2. Materials and methods
2.1 Search strategy
2.2 Study selection
2.3 Data collection
3.1 Results of the search
Our World in Data.
3.2 Characteristics of registered trials
|Number of Studies||137||57||50||309||95||264||129||259||8||1,308||-|
|Percent of Studies||11||4||4||24||7||20||10||20||1||100||-|
|Clinical Trial Registry|
|People's Republic of China||133||14||11||17||8||9||64||103||0||359||27|
|North America (US, Canada)||0||24||15||133||15||45||9||39||0||260||20|
|Central and South America||1||3||4||12||4||12||2||7||0||45||3|
|Adult and Pediatric||8||0||1||11||10||17||2||25||0||74||6|
3.3 Characteristics of interventions
|Intervention categories||N = 1,308 (% of total)||Intervention subcategories||(% of category)|
|Pharmacologic||765||58||Antiparasitics (± other)|
Immunomodulators (± other)
Antivirals (± other)
Traditional Chinese Medicine
|Biological||305||23||Monoclonal antibodies (± other)|
Plasma or IVIG
Stem cells (± other)
3.4 Characteristics of studied outcomes
4.1 Summary of findings
4.2 Strengths and limitations
4.3 Interpretations of findings
Coronavirus: countries where hydroxychloroquine is recommended.
- Mahevas M.
- Tran V.-T.
- Roumier M.
- Chabrol A.
- Paule R.
- Guillaud C.
- et al.
- Wu J.
- McCaffrey S.
4.4 Implications for practice
4.5 Implications for future research
CRediT authorship contribution statement
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 2020; 395: 507-513
- A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19).Infection. 2020; 24: 187-192
- Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia.N Engl J Med. 2020; 382: 1199-1207
- Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group.bioRxiv; Cold Spring Harbor, NY2020 (2020.02.07.937862)
- Clinical trial structures.J Exp Stroke Transl Med. 2010; 3: 8-18
- Naming the coronavirus disease (COVID-19) and the virus that causes it.(Available at)https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-itDate: 2020Date accessed: April 9, 2020
- A bibliometric analysis of COVID-19 research activity: a call for increased output.Cureus. 2020; 12: e7357
- Coronavirus disease 2019 (COVID-19) situation report – 51.in: Coronavirus disease (COVID-2019) situation reports. World Health Organization, Geneva, Switzerland2020
- An interactive web-based dashboard to track COVID-19 in real time.Lancet Infect Dis. 2020; 12: 533-534
- Clinical characteristics of coronavirus disease 2019 in China.N Engl J Med. 2020; 382: 1708-1720
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.Lancet Respir Med. 2020; 8: 475-481
- The response of Milan’s emergency medical system to the COVID-19 outbreak in Italy.Lancet. 2020; 395: e49-e50
- Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and Forecast during an emergency response.JAMA. 2020; (Epub ahead of print)
- How will country-based mitigation measures influence the course of the COVID-19 epidemic?.Lancet. 2020; 395: 931-934
- The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.Mil Med Res. 2020; 7: 11
- Randomized controlled trials: part 17 of a series on evaluation of scientific publications.Dtsch Arztebl Int. 2011; 108: 663-668
- Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov registry.Pediatrics. 2012; 130: e1269-e1277
- WHO International Clinical Trials Registry Platform (ICTRP).(Available at)
- medRxiv.(Available at)
- OSF.(Available at)
- Our World in Data.(Available at)https://ourworldindata.org/grapher/total-cases-covid-19?time=2020-01-23..2020-04-01Date accessed: April 4, 2020
- Exploring qualitative methods reported in registered trials and their yields (EQUITY): Systematic review.Trials. 2018; 19: 589
- Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective.Int J Biol Sci. 2020; 16: 1708-1717
- Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.Biosci Trends. 2020; 14: 72-73
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.Int J Antimicrob Agents. 2020; : 105949
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.Cell Discov. 2020; 6: 16
- Coronavirus: countries where hydroxychloroquine is recommended.(Available at)https://www.mediterranee-infection.com/coronavirus-pays-ou-lhydroxychloroquine-est-recommandee/Date: 2020Date accessed: April 6, 2020
- Coronavirus (COVID-19) Update: Daily Roundup March 30, 2020.U.S. Food and Drug Administration, Maryland, United States2020
- Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.medRxiv, Cold Spring Harbor, NY, United States2020 (2020.03.22.20040758)
- Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.medRxiv, Cold Spring Harbor, NY, United States2020 (2020.04.26.20081059)
- A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).J Zhejiang Univ. 2020; 49: 215-219
- Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial.medRxiv, Cold Spring Harbor, NY, United States2020 (2020.04.10.20060558)
- No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial.medRxiv, Cold Spring Harbor, NY, United States2020 (2020.04.10.20060699)
- Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.BJGP Open. 2020; 4: 1-7
- Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor.Arch Acad Emerg Med. 2020; 8: e17
- Arbidol as a broad-spectrum antiviral: an update.Antivir Res. 2014; 107: 84-94
- Oseltamivir for influenza infection in children: risks and benefits.Expert Rev Respir Med. 2016; 10: 79-87
- Remdesivir for the treatment of Covid-19 — preliminary report.N Engl J Med. 2020; (Epub ahead of print)
- Emory helps lead research on drug to treat COVID-19 patients.(Available at)https://news.emory.edu/stories/2020/04/coronavirus_emory_helps_lead_research_on_remdesivir/index.htmlDate: 2020Date accessed: March 30, 2020
- Remdesivir for 5 or 10 Days in patients with severe Covid-19.N Engl J Med. 2020; (Epub ahead of print)
- The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study.Lancet Public Health. 2020; 5: e261-e270
- The current challenges for vaccine development.J Med Microbiol. 2012; 61: 889-894
- Developing Covid-19 vaccines at pandemic speed.N Engl J Med. 2020; 382: 1969-1973
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.Lancet. 2020; 395: 1845-1854
- Choosing primary endpoints for clinical trials of health care interventions.Contemp Clin Trials Commun. 2019; 16: 100486
- Time to review the role of surrogate end points in health policy: state of the art and the way Forward.Value Health. 2017; 20: 487-495
- Publishing in the time of COVID-19.Elife. 2020; 9: 1-3
- Living systematic review: 1. Introduction-the why, what, when, and how.J Clin Epidemiol. 2017; 91: 23-30
- Living systematic reviews: 4. Living guideline recommendations.J Clin Epidemiol. 2017; 91: 47-53
Conflicts of interest: None to declare.